CI-994
HDAC inhibitor / Orally active histone deacetylase (HDAC) inhibitor, IC50 = 0.9, 0.9, 1.2 and >20 μM for HDAC1, HDAC2, HDAC3 and HDAC8 respectively.1 Mediates G1 cell cycle arrest, inhibits proliferation and induces apoptosis in vitro and in vivo.2,3 Increases neuroplasticity during memory extinction.4 Protects beta cells from cytokine-induced apoptosis.4
Biochemicals & reagents
112522-64-2
PD-123654; N-acetyl-dinaline; GOE-5549; Tacedinaline
1) Moradei et al. (2007), Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity; J. Med. Chem., 50 5543 2) Beckers et al. (2007), Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group; Int. J. Cancer, 121 1138 3) Loprevite et al. (2005), In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines; Oncol. Res., 15 39 4) Chou et al. (2012), Inhibition of histone deacetylase 3 protects beta cells from cytokine-induced apoptosis; Chem. Biol., 19 669
-20°C
TARGET: Protein deacetylase -- PATHWAY: Chromatin; Cell cycle; Apoptosis inducer; Cytokine; Posttranslational modification; Proliferation -- RESEARCH AREA: Epigenetics; Neuroscience; Cell death -- DISEASE AREA: Diabetes; Inflammation